Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas.

Human pathology - 1 Oct 2021

Shen Tiansheng, Wei Lai, Li Xiaoxian, Parwani Anil V, Li Zaibo

Abstract excerpt

Metastatic breast carcinomas (BCs) with phenotype of triple-negative (TNBC) or low hormonal receptor levels [estrogen receptor (ER)/progesterone receptor (PR) < 10% and HER2-] are mainly treated with cytotoxic chemotherapy. Targeting androgen receptor (AR) pathway may represent a potential new therapeutic strategy in such group of BCs. We evaluated AR expression by immunohistochemistry and genetic alterations by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Mutation

Share to Prognosis

Share to Receptors, Androgen

Share to Transcription Factors

Source

Identifiers

PMID: 34310983
DOI: 10.1016/j.humpath.2021.07.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas.PMID 34310983Read ↗

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.Semantic proximity Read ↗

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.Semantic proximity Read ↗

Assessing the Androgen Receptor Status in Clinicopathologic and Hematologic Characteristics of the Triple-negative Breast CancerSemantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

[Androgen receptor-positive triple negative breast cancer: From biology to therapy].Semantic proximity Read ↗

Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?Semantic proximity Read ↗

Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.Semantic proximity Read ↗

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.Semantic proximity Read ↗

An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancersSemantic proximity Read ↗

Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.Semantic proximity Read ↗

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancerSemantic proximity Read ↗

Frequency of genetic alterations differs in advanced breast cancer between metastatic sites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.